Record growth at The Wasdell Group7 Nov 2018
Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.
The Wasdell Group, an outsourcing partner for the pharmaceutical, medical device and clinical development and manufacturing industries, has experienced over 40% revenue growth in the last 24 months, following an increase in demand for its clinical trial, manufacturing and packing services.
Wasdell enter the final quarter of 2018 with a revenue of £41M, a considerable increase compared with £28M in 2016. This record growth has allowed the company to expand its clinical development, manufacturing and packaging capabilities, as well as invest in an on-site laboratory and build its first site outside of the UK.
Martin Tedham, CEO at The Wasdell Group said: “Our strong growth can be largely attributed to the number of pre-clinical development projects that we have recently been awarded, as well as our ongoing work in our manufacturing division.
“It is clear we are becoming more established across the pharmaceutical sector for our efficient service and ability to support customers with end-to-end supply needs. We are not only receiving an influx of new business, but more of our customers are also recognising the advantages of outsourcing more of their operations to Wasdell.”
Following the completion of building work on its new site in Dundalk, Ireland – due to finish in spring 2019 – the company will add 300 new members of staff to its team talking the total number of employees to 1000.
Martin continued: “Despite Brexit looming, our EU & UK business has increased by almost 30% in the last 12 months. We have also strengthened our partnerships with a number of US customers as a result of futureproofing our position as a reliable stepping stone into European market.
“Looking back to 2009 we were turning over just under £2m so to hit our £40M target fills me with a huge amount of pride and gratitude to our customers and our employees. I believe the customer-centric approach Wasdell has always taken, whether it be in delivery of our work or in the investments we have made, has played a huge part in our success today. I can’t wait to see what the future holds.”
Wasdell has ongoing plans to continue investing in its manufacturing and distribution facilities across the UK, especially at its Swindon site which is set to expand in 2019. This next round of investment will cater for the company’s forecasted growth which is estimated to increase by a further 25% by 2020.
Specialist API CDMO acquired by GHO Capital
16 Mar 2019
Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.Read more
Bringing next generation single-use sensor technologies to the life science market
14 Mar 2019
Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.Read more
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program
12 Mar 2019
Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.Read more
Overcoming lyophilization challenges at Interphex 2019
10 Mar 2019
Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.Read more
Catalent invests over $27 million to commercialize Zydis Ultra
7 Mar 2019
Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.Read more
Novel systems for membrane chromatography
6 Mar 2019
Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.Read more
Lilly to introduce lower-priced insulin
5 Mar 2019
Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.Read more
Biogen acquisition boosts its ophthalmology pipeline
4 Mar 2019
Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.Read more
Uniqsis expands LED photoreactor range
3 Mar 2019
The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation